SSA
TBPH icon

Sierra Summit Advisors’s Theravance Biopharma TBPH Stock Holding History

Sierra Summit Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1M Buy
+59,096
New +$978K 0.11% 135
2026
Q1 		– Sell
-59,371
Closed -$1.11M – 218
2025
Q4 		$1.11M Buy
+59,371
New +$985K 0.17% 75

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Sierra Summit Advisors's TBPH Position: Q2 2026 in Review

Sierra Summit Advisors opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 59,096 shares worth $1M. The stake represents 0.11% of the portfolio and ranks #135 among its holdings. This is a return to the name: Sierra Summit Advisors previously reported a position in TBPH as recently as Q4 2025.

Sierra Summit Advisors first reported a position in TBPH in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.11M in Q4 2025. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Sierra Summit Advisors held 59,096 shares of Theravance Biopharma worth $1M as of Q2 2026.
  • Theravance Biopharma was a new Sierra Summit Advisors position in Q2 2026.
  • Theravance Biopharma made up 0.11% of Sierra Summit Advisors's portfolio in Q2 2026, its #135 holding.
  • Sierra Summit Advisors first reported a position in Theravance Biopharma in Q4 2025 and has held it in 2 quarters since.
  • Sierra Summit Advisors's Theravance Biopharma position peaked at $1.11M in Q4 2025.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Sierra Summit Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.